Pharmacy board suspends another Ohio weight loss clinic's license
Ohio weight-loss clinics continue to be disciplined over alleged unsafe practices and false claims that they pass regulatory muster.
The actions come as demand skyrockets for drugs similar to those that go by the brand names Ozempic, Wegovy, Zepbound and Mounjaro.
The Ohio Board of Pharmacy notified Slimbolic Weight Loss and Med Spa in Beavercreek that its license to distribute dangerous drugs was summarily suspended. The notice was accompanied by a 29-page document listing scores of alleged violations.
They included naming as the person responsible for the clinic a Maine doctor who had never been there, improper recordkeeping, storing adulterated drugs with those that weren't, and improperly labeled drugs. Pharmacy board inspectors said workers at the clinic were also compounding drugs without the proper supervision and that they were doing so in a non-sterile environment.
SUBSCRIBE: GET THE MORNING HEADLINES DELIVERED TO YOUR INBOX
The order said 'there is clear and convincing evidence of a danger of immediate and serious harm to others due to Slimbolic's method used to possess or distribute dangerous drugs, and the method of prescribing dangerous drugs used by a licensed health professional authorized to prescribe drugs who holds a terminal distributor license or practices in the employ of or under contract with a terminal distributor.'
A call placed to the clinic was not returned.
The board of pharmacy has been cracking down on weight-loss clinics as the clamor for GLP-1 drugs has risen. They facilitate weight loss by slowing gastric emptying. The resultant weight loss can ease impacts of obesity, including diabetes and heart disease.
But the pharmacy board has reported numerous abuses by Ohio spas and weight-loss clinics over the past year.
In January, the board suspended licenses to distribute dangerous drugs held by clinics in Cleveland, Cincinnati, Dayton and Columbus. It accused them of giving patients weight-loss drugs that were labeled 'for research use only' and that came from 'an unlicensed out-of-state-seller.'
In March, it suspended the license of Rejuv and Renew Wellness Spa, which has clinics in Maineville and Franklin, both in Warren County between Cincinnati and Dayton. The board said the spa was injecting patients with 'counterfeit' Botox that the operator said she'd gotten from a California dentist she wouldn't identify.
In a related matter, Ohio Attorney General Dave Yost recently warned 14 spas 'to stop making false or misleading claims about their versions of popular weight-loss drugs.'
'People deserve clear and accurate information about the medications they're putting in their bodies,' Yost said in a written statement. 'We're reminding businesses that being truthful isn't just a good business practice — it's the law.'
SUPPORT: YOU MAKE OUR WORK POSSIBLE
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 hours ago
- Yahoo
Weight-loss jabs could help obese people control asthma, study suggests
Weight-loss jabs could help minimise asthma symptoms in obese people, according to a study. The drugs should be explored as a potential treatment for obese people with the respiratory condition, who are 'often resistant' to steroids, researchers said. Weight-loss jabs, also known as glucagon-like peptide1 receptor-agonists (GLP1-RAs), work by mimicing the hormone GLP-1 to regulate blood sugar and insulin levels. They were initially developed as a treatment for people with type 2 diabetes. A number of types of the drug are recommended to help tackle obesity on the NHS, including semaglutide, or Wegovy, and tirzepatide, or Mounjaro. Previous studies have suggested the drugs may slash the risk of illnesses like dementia and stroke, with an international team of experts exploring their potential impact on obese people with asthma. Professor David Price, University of Aberdeen chair in primary care respiratory medicine, said: 'People with obesity and asthma are unique in that they are often resistant to steroid treatments. 'We know that GLP1s work on inflammatory responses in the airways in a different way to traditionally used steroids.' For the study, published in Advances in Therapy, researchers analysed the records of 10,111 people on GLP1-RAs and 50,555 people who were not on the drugs. After a follow-up period, the team found that those taking weight-loss jabs lost more weight and had improved asthma control. Researchers said the findings suggest medics 'should pay attention to the relationship between GLP-1 RA and the risk of respiratory diseases'. Prof Price added: 'We found compelling evidence that GLP1s, as well as increasing weight loss, also improved asthma symptoms. 'In addition, it is important to note that the benefits to asthma symptoms occurred despite fairly modest weight loss of around 0.9kg over the course of the year. 'Our findings suggest that GLP1s may have beneficial effects on asthma control for people with obesity and this should be explored further.' Prof Alan Kaplan, chairperson of the Family Physician Airways Group of Canada and the Observational and Pragmatic Research Institute, said: 'Our findings suggest that GLP1-RAs have benefits on asthma control in people with obesity, and this information should contribute to the discussions around the decision to use these drugs.' Dr Erika Kennington, head of research and innovation at Asthma and Lung UK, said: 'Research has previously shown that people living with obesity who lose weight see improved control of their asthma, so it's encouraging to see this study show this is still the case when the weight loss is driven by drugs, like the new class of weight loss drugs. 'Although exercise can help people lose weight, for some people it can cause anxiety about becoming breathless or having an asthma attack, so people are stuck in a vicious cycle of not being able to lose weight and their asthma worsening. 'Therefore, where exercise hasn't worked for someone these drugs that support weight loss could offer a promising alternative. 'It's too early to say whether these drugs would be effective for people with asthma more widely. 'More research is needed to understand how these drugs actually improve asthma control. Funding for lung health research is on life support and urgent action is needed to increase investment.'
San Francisco Chronicle
3 hours ago
- San Francisco Chronicle
Bid by S.F.'s largest nursing home to restore 120 beds rejected by federal regulators
San Francisco's largest skilled nursing home, Laguna Honda, will not be able to reinstate 120 beds — which would have improved capacity for such care in the rapidly aging city — after federal regulators this month denied the hospital's attempt to gain approval for the expansion. The Centers for Medicare and Medicaid Services (CMS) turned down Laguna Honda's request to reinstate the beds, citing federal regulations that require nursing facilities certified after 2016 to limit residents to two per room. Reinstating the 120 beds would have meant Laguna Honda would have three residents in some of its rooms. CMS can make an exception to this rule by granting nursing homes a waiver allowing them more than two residents per room if they can show it meets residents' needs and will not harm their health and safety. Laguna Honda sought such a waiver in April, and was notified by CMS on July 7 that it was denied. In a letter to Laguna Honda leaders, CMS cited concerns about privacy, infection control and resident safety. It also cited hundreds of allegations of non-compliance, including allegations of abuse, neglect and resident rights violations since the hospital was recertified in 2023. Laguna Honda leaders said this was a 'gross mischaracterization' and that only six of the 276 allegations of non-compliance resulted in a cited deficiency, and that for each deficiency, the hospital completed a plan of correction. Compared to other large nursing facilities in California, Laguna Honda ranks in the middle for reported incidents and below the median for deficiencies, they said. 'We are very disappointed,' said Roland Pickens, director of San Francisco Health Network, which is owned and operated by the San Francisco Department of Public Health and includes Laguna Honda. Since 2010, Laguna Honda had 769 beds and housed three residents in some rooms, known as triples, because federal regulations allow that for nursing homes certified before 2016. But in 2022, the hospital lost its Medicare certification after state inspectors identified moderate to very serious deficiencies at the facility, including many residents testing positive for narcotics. The inspection was launched in 2021 after two residents overdosed but survived. During the process of regaining Medicare certification — a two-year saga that threatened to shut down the facility altogether — Laguna Honda had to decommission the triple rooms, reducing its skilled nursing beds from 769 to 649. It regained Medicare certification in 2024, which means it must comply with the regulation that limits residents to two per room for facilities certified after 2016. Laguna Honda then sought the waiver to add back the 120 beds, citing the critical need for skilled nursing care in San Francisco. The facility currently has about 550 residents. Laguna Honda leaders said they strongly disagree with CMS's decision but will not appeal or seek litigation challenging it. 'Pursuing legal action would be costly, time consuming and unlikely to yield a timely or favorable result — especially given CMS's broad discretion and the current political climate,' the public health department said. 'In the face of ongoing federal and state threats to Medicaid funding, local health departments like SFDPH must focus on protecting the broader system of care.'
Chicago Tribune
4 hours ago
- Chicago Tribune
UnitedHealth says it is under a federal investigation and cooperating
UnitedHealth Group says it is cooperating with federal criminal and civil investigations involving its market-leading Medicare business. The health care giant said Thursday that it had contacted the Department of Justice after reviewing media reports about investigations into certain elements of its business. '(UnitedHealth) has a long record of responsible conduct and effective compliance,' the company said in a Securities and Exchange Commission filing. Earlier this year, The Wall Street Journal said federal officials had launched a civil fraud investigation into how the company records diagnoses that lead to extra payments for its Medicare Advantage, or MA, plans. Those are privately run versions of the government's Medicare coverage program mostly for people ages 65 and over. The company's UnitedHealthcare business covers more than 8 million people as the nation's largest provider of Medicare Advantage plans. The business has been under pressure in recent quarters due to rising care use and rate cuts. The Journal said in February, citing anonymous sources, that the probe focused on billing practices in recent months. The paper has since said that a federal criminal health care-fraud unit was investigating how the company used doctors and nurses to gather diagnoses that bolster payments. UnitedHealth said in the filing Thursday that it 'has full confidence in its practices and is committed to working cooperatively with the Department throughout this process.' UnitedHealth Group Inc. runs one of the nation's largest health insurance and pharmacy benefits management businesses. It also operates a growing Optum business that provides care and technology support. UnitedHealth raked in more than $400 billion in revenue last year to come in third in the Fortune 500 list of biggest U.S. companies. Its share price topped $630 last fall to reach a new all-time high. But the stock has mostly shed value since December, when UnitedHealthcare CEO Brian Thompson was fatally shot in midtown Manhattan on his way to the company's annual investor meeting. A suspect, Luigi Mangione, has been charged in connection with the shooting. In April, shares plunged some more after the company cut its forecast due to a spike in health care use. A month later, former CEO Andrew Witty resigned, and the company withdrew its forecast entirely, saying that medical costs from new Medicare Advantage members were higher than expected. The stock price was down more than 3%, or $10.73, to $281.78 Thursday afternoon. That represents a 55% drop from the all-time high it hit in November. Broader indexes were mixed. UnitedHealth will report its second-quarter results next Tuesday.
